significantly enhance the likelihood of a woman enjoying sex and having orgasm

More studies are planned with the compound bremelanotide to test its safety and effectiveness for the treatment of female sexual dysfunction. Palatin Technologies in a press release said that they had started a Phase 2b study which they hoped to have completed by the second half of 2012. For the study they will be monitoring the number of satisfying sexual events recorded by the female volunteers as well as noting side effects and any other problems associated with its use.

The study will be conducted in various different places around America and will be following a placebo and randomized format. All of the participants will be premenopausal women suffering from female sexual dysfunction and it is hoped to have as many as 400 of them. Different doses of the bremelanotide will be administered to the women as well as the placebo.

Bremelanotide which was previously code named PT-141 is a drug which works on receptors in the brain and has been shown to significantly enhance the likelihood of a woman enjoying sex and having an orgasm.

The study results will be used by Palatin to show the FDA that the drug is both safe and effective and should be licensed for sale. Many people have speculated that bremelanotide could become the female Viagra or pink Viagra which would earn billions of pounds for its manufacturer.

Studies show that women suffer from a range of sexual disorders which make it very difficult for them to enjoy sex. Unlike men who tend to respond more to physical stimulation, women usually require psychological help in order to deal with their sexual problems. It has also been observed that men respond well to using bremelanotide too which could lead to it becoming a universal lovemaking medication.

At present the only drug which women can take to improve their sex lives is the prescription medication Intrinsa.